Life Science Investing Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
Life Science Investing Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis
Life Science Investing Eupraxia Pharmaceuticals Provides Update for Phase 2 Study in Knee Osteoarthritis for Lead Drug Candidate EP-104IAR
Life Science Investing Eupraxia Pharmaceuticals Announces Expansion of Intellectual Property For EP-104IAR
Life Science Investing Eupraxia Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
Life Science Investing Eupraxia Pharmaceuticals Recognized as Emerging Life Sciences Company of the Year by Life Sciences British Columbia
Brunswick Exploration Drills 36 Meters at 1.51% and Continues to Extend the Mineralized Footprint of Mirage
